NYMOX PHARMACEUTICAL CORP (NYMX)       0.42  +0.01 (+1.3%)

0.42  +0.01 (+1.3%)

BSP733981026 - Common Stock - Premarket: 0.4027 -0.02 (-4.12%)


Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NYMX. NYMX was compared to 635 industry peers in the Biotechnology industry. NYMX has a bad profitability rating. Also its financial health evaluation is rather negative. NYMX is valued expensive and it does not seem to be growing.

Note: NYMX has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

The Piotroski-F score of NYMX is 4.00. This is a neutral score and indicates average health and profitability for NYMX.
The profitability ratios for NYMX are negative, so there is not much use analyzing them.

NYMX has a Return On Assets of -256.19%. This is below the industry average of -44.83%. 97% of the industry peers outperform NYMX.
VS Industry

ROA (-256.19%) VS Industry: 3% outperformed.

-3,944.82
115.38

Valuation

Valuation Rating

0

The Price/Earnings Ratio is negative for NYMX. In the last year negative earnings were reported.
With a price book ratio of 49.59, NYMX is valued rather expensively.

When comparing the price book ratio of NYMX to the average industry price book ratio of 1.69, NYMX is valued more expensive than its industry peers. 99% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Book (49.59) VS Industry: 1% outperformed.

140.12
0.10

Growth

Growth Rating

2

NYMX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.69%, which is quite impressive.

Looking at the last year, NYMX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 35.69% N/A N/A N/A N/A
RevenueN/A N/A -100% N/A N/A N/A N/A

Health

Health Rating

2

NYMX has a Current Ratio of 1.24. This is a normal value and indicates that NYMX is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.22 indicates that NYMX should not have too much problems paying its short term obligations.
Compared to an average industry Debt to Equity Ratio of 0.00, NYMX is more dependent on financing than its industry peers.
We won't put much weight on the industry comparison as NYMX has a very low Debt to Equity (0.01).
NYMX has a Piotroski-F score of 4.00. This indicates an average health and profitability for NYMX.

When comparing the Current Ratio of NYMX to the average industry Current Ratio of 6.11, NYMX is less able to pay its short term obligations than its industry peers. 92% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 6.02, NYMX is worse placed to pay its short term obligations than its industry peers. 91% of its industry peers have a better Quick Ratio.
Based on the Altman-Z score of -93.02, we must say that NYMX is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.65, NYMX is in worse financial state than most of its industry peers. 100% of its industry peers have a better Altman-Z score.
VS Industry

Debt/Equity (0.01) VS Industry: 33% outperformed.

15.37
0.00

Quick Ratio (1.22) VS Industry: 9% outperformed.

0.02
84.53

Current Ratio (1.24) VS Industry: 8% outperformed.

0.02
85.09

Altman-Z (-93.02) VS Industry: 0% outperformed.

-1,822.12
441.73

Dividend

Dividend Rating

0

No dividends for NYMX!.

NYMX Daily chart

NYMOX PHARMACEUTICAL CORP0.42

NASDAQ:NYMX (12/6/2022, 9:52:00 PM)+0.01 (+1.3%)

Premarket: 0.4027 -0.02 (-4.12%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-16 2022-11-16/dmh Earnings (Next) N/A N/A
Ins Owners 5.15% Inst Owners 0.72%
Market Cap 38.33M Analysts N/A
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 49.59
EV/EBITDA -2.13
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y 35.69% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 58.51%
EPS Next Y N/A EPS Next 2Y N/A
EPS Next 3Y N/A EPS Next 5Y N/A
Revenue growth 1Y -100% Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 1.24 Quick Ratio 1.22
Altman-Z -93.02 F-Score 4
Debt/Equity 0.01 WACC 8.82%
ROIC/WACC N/A
Profitability
ROA -256.19% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA